Rita Laiginhas1,2, Marta Inês Silva1, Vitor Rosas1, Susana Penas1, Vitor Adriano Fernandes1, Amândio Rocha-Sousa1,3, Ângela Carneiro1,3, Fernando Falcão-Reis1,3, Manuel Sousa Falcão4,5. 1. Department of Ophthalmology, Centro Hospitalar de São João, Porto, Portugal. 2. Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal. 3. Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. 4. Department of Ophthalmology, Centro Hospitalar de São João, Porto, Portugal. falcao@med.up.pt. 5. Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. falcao@med.up.pt.
Abstract
PURPOSE: To evaluate functional and anatomical outcomes after aflibercept in patients with diabetic macular edema (DME) with poor response to bevacizumab. METHODS: We retrospectively reviewed patients with DME recalcitrant to bevacizumab who were switched to aflibercept between January and December 2015. All patients had a minimal follow-up of three months before the conversion and underwent at least three injections of bevacizumab. Functional outcome consisted in best corrected visual acuity (VA). Anatomical outcomes were demonstrated through central macular thickness (CMT) measured by optical coherence tomography. RESULTS: Forty-nine eyes of 34 subjects were reviewed. Mean VA improved from 0.55 ± 0.32 logMAR to 0.46 ± 0.33 logMAR (p = 0.038). Mean CMT decreased from 473 ± 146 μm to 349 ± 85 μm (p < 0.001). Twelve eyes (24%) demonstrated absence of macular edema after aflibercept. Previous bevacizumab exposure did not correlate with different outcomes. The variation of VA in response to aflibercept was significantly superior in the group with poorer VA before the switch (mean variation of -0.097 ± 0.21 logMAR) when compared to eyes with VA < 0.4 logMAR (mean variation of +0.019 ± 0.090 logMAR; p = 0.036). The same scenario was verified for anatomical outcomes as eyes with poor vision before the switch (≥0.4 logMAR) achieved superior reduction in CMT in response to aflibercept (mean CMT variation of -157 ± 171 μm versus -49.5 ± 39.9 μm; p < 0.01). Pre-switch CMT was a predictor of CMT reduction after switching (B = -0.945; confidence interval 95% -1.1; -0.76; p < 0.001). CONCLUSIONS: Conversion to aflibercept for persistent DME resulted in functional and anatomical improvements and these outcomes were not influenced by previous bevacizumab exposure. Pre-switch CMT was a predictor of anatomical changes after aflibercept.
PURPOSE: To evaluate functional and anatomical outcomes after aflibercept in patients with diabetic macular edema (DME) with poor response to bevacizumab. METHODS: We retrospectively reviewed patients with DME recalcitrant to bevacizumab who were switched to aflibercept between January and December 2015. All patients had a minimal follow-up of three months before the conversion and underwent at least three injections of bevacizumab. Functional outcome consisted in best corrected visual acuity (VA). Anatomical outcomes were demonstrated through central macular thickness (CMT) measured by optical coherence tomography. RESULTS: Forty-nine eyes of 34 subjects were reviewed. Mean VA improved from 0.55 ± 0.32 logMAR to 0.46 ± 0.33 logMAR (p = 0.038). Mean CMT decreased from 473 ± 146 μm to 349 ± 85 μm (p < 0.001). Twelve eyes (24%) demonstrated absence of macular edema after aflibercept. Previous bevacizumab exposure did not correlate with different outcomes. The variation of VA in response to aflibercept was significantly superior in the group with poorer VA before the switch (mean variation of -0.097 ± 0.21 logMAR) when compared to eyes with VA < 0.4 logMAR (mean variation of +0.019 ± 0.090 logMAR; p = 0.036). The same scenario was verified for anatomical outcomes as eyes with poor vision before the switch (≥0.4 logMAR) achieved superior reduction in CMT in response to aflibercept (mean CMT variation of -157 ± 171 μm versus -49.5 ± 39.9 μm; p < 0.01). Pre-switch CMT was a predictor of CMT reduction after switching (B = -0.945; confidence interval 95% -1.1; -0.76; p < 0.001). CONCLUSIONS: Conversion to aflibercept for persistent DME resulted in functional and anatomical improvements and these outcomes were not influenced by previous bevacizumab exposure. Pre-switch CMT was a predictor of anatomical changes after aflibercept.
Authors: Jeffrey S Heier; Neil M Bressler; Robert L Avery; Sophie J Bakri; David S Boyer; David M Brown; Pravin U Dugel; K Bailey Freund; Adam R Glassman; Judy E Kim; Daniel F Martin; John S Pollack; Carl D Regillo; Philip J Rosenfeld; Andrew P Schachat; John A Wells Journal: JAMA Ophthalmol Date: 2016-01 Impact factor: 7.389
Authors: Alok S Bansal; Rahul N Khurana; Mark R Wieland; Pin-Wen Wang; Sherri A Van Everen; Lisa Tuomi Journal: Ophthalmology Date: 2015-06-04 Impact factor: 12.079
Authors: Ehsan Rahimy; Abtin Shahlaee; M Ali Khan; Gui-Shuang Ying; Joseph I Maguire; Allen C Ho; Carl D Regillo; Jason Hsu Journal: Am J Ophthalmol Date: 2015-12-31 Impact factor: 5.258
Authors: Eric L Ross; David W Hutton; Joshua D Stein; Neil M Bressler; Lee M Jampol; Adam R Glassman Journal: JAMA Ophthalmol Date: 2016-08-01 Impact factor: 7.389
Authors: Osama A Sorour; Almyr S Sabrosa; A Yasin Alibhai; Malvika Arya; Akihiro Ishibazawa; Andre J Witkin; Caroline R Baumal; Jay S Duker; Nadia K Waheed Journal: Int Ophthalmol Date: 2019-05-22 Impact factor: 2.031
Authors: Osama A Sorour; Keke Liu; Nihaal Mehta; Phillip Braun; Isaac Gendelman; Elsayed Nassar; Caroline R Baumal; Andre J Witkin; Jay S Duker; Nadia K Waheed Journal: Int J Retina Vitreous Date: 2020-06-08